Incidence and Survival by Human Epidermal Growth Factor Receptor-2 Status in Young Women with Stage I-III Breast Cancer: SEER 2010–2016

Details

• Alternative Title:
  Clin Breast Cancer
• Personal Author:
  Thomas, Alexandra ; Rhoads, Anthony ; Suhl, Jonathan ; Conway, Kristin M ; Hundley, William G ; McNally, Lacey R ; Oleson, Jacob ; Melin, Susan A ; Lynch, Charles F ; Romitti, Paul A
• Description:
  Background:
  
  Young, premenopausal women with breast cancer often experience more aggressive disease biology and poorer survival than older women. Diagnostic and therapeutic advances, including human epidermal growth factor receptor-2 (HER2)-directed therapy, may lessen treatment burden and improve survival for these young women, but contemporary incidence and survival data by HER2 status are limited.
  
  Patients and Methods:
  
  We identified women aged 20–49 years (n=68,530) diagnosed with stage I-III breast cancer during 2010–2016 from the United States Surveillance, Epidemiology and End Results 18 registries database. Age-adjusted, average annual percentage changes in incidence (diagnosis 2010–2016) and five-year Kaplan-Meier survival curves (diagnosis 2010–2015) were estimated by HER2 and hormone receptor (HR) status and stratified independently by cancer stage and race/ethnicity.
  
  Results:
  
  With increasing age decade, proportions of HER2−/HR+ cancer increased, whereas proportions of HER2+/HR+, HER2+/HR−, and HER2−/HR− decreased. The greatest increases in incidence during 2010–2016 were observed for HER2+ among women 20–49 and HER2−/HR− among women 20–29. Incidence decreased for HER2−/HR− among women 40–49. Five-year survival was lowest for HER2−/HR− status compared to other receptor-based subtypes among women 20–49. HER2+ status was more beneficial for five-year survival than HR+ status among women 20–29, with the opposite observed among women 30–49, particularly those 40–49.
  
  Conclusions:
  
  HER2+ breast cancer increased among premenopausal women and was also associated with higher early survival within each HR status. HER2−/HR− cancer also increased among women 20–29 and was associated with lower early survival. Our contemporary data provide important insights to help inform preventive and therapeutic strategies for premenopausal women.
  
  
• Subjects:
  Adult Biomarkers, Tumor Breast Breast Neoplasms Female Humans Incidence Kaplan-Meier Estimate Middle Aged Neoplasm Staging Premenopause Prognosis Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Retrospective Studies SEER Program United States Young Adult

  More +
• Keywords:
  Genes HER2 Survival
• Source:
  Clin Breast Cancer. 20(4):e410-e422
• Pubmed ID:
  32278642
• Pubmed Central ID:
  PMC7398833
• Document Type:
  Journal Article
• Funding:
  U01DD001035/ACL/ACL HHSUnited States/ ; U01 DD001223/DD/NCBDD CDC HHSUnited States/ ; HHSN261201300020I/CA/NCI NIH HHSUnited States/ ; P30 CA086862/CA/NCI NIH HHSUnited States/ ; U01 DD001035/DD/NCBDD CDC HHSUnited States/ ; HHSN261201300021C/CA/NCI NIH HHSUnited States/ ; U01DD001223/ACL/ACL HHSUnited States/ ; HHSN261201300020C/CA/NCI NIH HHSUnited States/
• Volume:
  20
• Issue:
  4
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:114fa50c9bf63dc9d2e89cfde8a1cda6365d48987729a1477ca21242509391e49bfff202de3e65c3b687280500ce612f091d9edfa45fa8db7867626b534e9dc4
• Download URL:
  https://stacks.cdc.gov/view/cdc/91511/cdc_91511_DS1.pdf
• File Type:
  [PDF - 425.81 KB ]